- Home
- WVE vs AZTA Comparison
WVE vs AZTA Comparison
Compare WVE & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- AZTA
- Stock Information
- Founded
- WVE 2012
- AZTA 1978
- Country
- WVE Singapore
- AZTA United States
- Employees
- WVE N/A
- AZTA N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- AZTA Industrial Machinery/Components
- Sector
- WVE Health Care
- AZTA Technology
- Exchange
- WVE Nasdaq
- AZTA Nasdaq
- Market Cap
- WVE 1.7B
- AZTA 1.8B
- IPO Year
- WVE 2015
- AZTA 1995
- Fundamental
- Price
- WVE $7.74
- AZTA $34.12
- Analyst Decision
- WVE Strong Buy
- AZTA Buy
- Analyst Count
- WVE 11
- AZTA 4
- Target Price
- WVE $22.00
- AZTA $58.75
- AVG Volume (30 Days)
- WVE 1.3M
- AZTA 707.0K
- Earning Date
- WVE 03-04-2025
- AZTA 05-07-2025
- Dividend Yield
- WVE N/A
- AZTA N/A
- EPS Growth
- WVE N/A
- AZTA N/A
- EPS
- WVE N/A
- AZTA N/A
- Revenue
- WVE $108,302,000.00
- AZTA $662,108,000.00
- Revenue This Year
- WVE N/A
- AZTA N/A
- Revenue Next Year
- WVE $33.28
- AZTA $5.44
- P/E Ratio
- WVE N/A
- AZTA N/A
- Revenue Growth
- WVE N/A
- AZTA 5.36
- 52 Week Low
- WVE $4.25
- AZTA $33.33
- 52 Week High
- WVE $16.74
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- WVE 31.52
- AZTA 27.36
- Support Level
- WVE $9.43
- AZTA $33.33
- Resistance Level
- WVE $10.91
- AZTA $38.57
- Average True Range (ATR)
- WVE 0.63
- AZTA 1.66
- MACD
- WVE -0.18
- AZTA -0.03
- Stochastic Oscillator
- WVE 3.21
- AZTA 14.68
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.